Form 4: Director Daniel J. Curran Receives Xilio Stock Options

Director Daniel J. Curran was granted 5,000 stock options in Xilio Therapeutics, Inc. on June 11, 2026.

Summary

• Director Daniel J. Curran received a grant of 5,000 stock options for Xilio Therapeutics, Inc. (XLO) common stock.
• The options have an exercise price of $7.99 per share.
• The grant date is June 11, 2026, with an expiration date of June 10, 2036.
• The options vest 100% on the earlier of June 11, 2027, or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is subject to the director's continued service to the issuer.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant of 5,000 options is consistent with standard director compensation packages for small-cap biotechnology firms.
• The one-year cliff vesting schedule is a common practice for director equity awards.

Corporate Governance

Stakeholder Impact

• Minor dilution impact on existing shareholders.

Next Steps

• Vesting of options on June 11, 2027, or the next annual meeting.

Key Dates

Keywords

Xilio Therapeutics, XLO, Form 4, Insider Trading, Stock Options, Director Compensation